Stem cells

Stem cell therapy company Amniotics raises SEK 60 million before deduction of transaction costs, in First North IPO to advance lead candidate PulmoStem™ into clinic

Retrieved on: 
Monday, July 12, 2021
Branches of biology, Biology, Life sciences, Stem cells, Stem-cell therapy, Mesenchymal stem cell, Amniotic fluid, Biocell Center

LUND, Sweden, July 12, 2021 /PRNewswire/ -- Amniotics AB (publ) ("Amniotics" or the "Company"), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market.

Key Points: 
  • LUND, Sweden, July 12, 2021 /PRNewswire/ -- Amniotics AB (publ) ("Amniotics" or the "Company"), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market.
  • The funds will now be deployed to advance the company's preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid.
  • Lead candidate PulmoStem, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic in Q2, 2022.
  • With the proceeds from the IPO, Amniotics has the financial resources required to move our lead candidate PulmoStem into clinical development.

Stem cell therapy company Amniotics raises SEK 60 million before deduction of transaction costs, in First North IPO to advance lead candidate PulmoStem™ into clinic

Retrieved on: 
Monday, July 12, 2021
Branches of biology, Biology, Life sciences, Stem cells, Stem-cell therapy, Mesenchymal stem cell, Amniotic fluid, Biocell Center

LUND, Sweden, July 12, 2021 /PRNewswire/ -- Amniotics AB (publ) ("Amniotics" or the "Company"), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market.

Key Points: 
  • LUND, Sweden, July 12, 2021 /PRNewswire/ -- Amniotics AB (publ) ("Amniotics" or the "Company"), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market.
  • The funds will now be deployed to advance the company's preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid.
  • Lead candidate PulmoStem, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic in Q2, 2022.
  • With the proceeds from the IPO, Amniotics has the financial resources required to move our lead candidate PulmoStem into clinical development.

PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)

Retrieved on: 
Friday, July 9, 2021
Research, Stem cells, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Branches of biology, Biology, Stem cells, Blood cells, Cell biology, Cancer immunotherapy, Biotechnology, Cell therapy, Acute myeloid leukemia, Immunotherapy, Hematopoietic stem cell, Haematopoiesis, Vor Biopharma, PureTech Health, VOR BIOPHARMA, PURETECH HEALTH

The collaboration agreement provides that each company retains all rights and ownership to their respective programs and platforms.

Key Points: 
  • The collaboration agreement provides that each company retains all rights and ownership to their respective programs and platforms.
  • We believe this unique combination will leverage each technologys strengths, while protecting patients against off-target effects of these powerful immunotherapies.
  • Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies.
  • Forward-looking statements in this press release include the Companys statements regarding its platforms potential to treat patients suffering from acute myeloid leukemia.

Lysogene Announces FDA Fast Track Designation for LYS-GM101 Gene Therapy for the Treatment of GM1 Gangliosidosis

Retrieved on: 
Thursday, July 8, 2021
Stem cells, Biotechnology, Pharmaceutical, Health, FDA, Genetics, Clinical trials, Other Health, Lipid storage disorders, Rare diseases, Branches of biology, Life sciences, Biology, Glycolipids, Gangliosidosis, GM1 gangliosidoses, GLB1, Ganglioside, GM1, Fast track

GM1 gangliosidosis is a fatal autosomal recessive disease caused by mutations in the GLB1 gene leading to accumulation of GM1 ganglioside in neurons resulting in progressive neurodegeneration.

Key Points: 
  • GM1 gangliosidosis is a fatal autosomal recessive disease caused by mutations in the GLB1 gene leading to accumulation of GM1 ganglioside in neurons resulting in progressive neurodegeneration.
  • A product that receives Fast Track designation is eligible for more frequent interactions with FDA, potential eligibility for accelerated approval, priority review, and rolling Biologics License Application (BLA) review.
  • This Fast Track designation demonstrates the regulators sustained interest in Lysogenes cutting edge gene therapy program.
  • Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS).

PharmaCyte Biotech Announces Results of Vote at Annual Meeting of Stockholders

Retrieved on: 
Thursday, July 8, 2021
Oncology, Health, Communications, Medical devices, Diabetes, General Health, Public relations, Investor relations, Medical technology, Branches of biology, Life sciences, Biomaterials, Biomedical engineering, Cell encapsulation, Regenerative biomedicine, Tissue engineering, Stem cells

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that all 4 proposals presented to the Companys stockholders for a vote at the 2021 Annual Meeting of Stockholders have passed.

Key Points: 
  • PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that all 4 proposals presented to the Companys stockholders for a vote at the 2021 Annual Meeting of Stockholders have passed.
  • PharmaCytes 2021 Annual Meeting of Stockholders was held on June 16, 2021, and then adjourned until voting concluded on June 30, 2021.
  • The following proposals were approved at the Annual Meeting:
    Proposal One: To elect seven directors as nominated by the Board of Directors, each to serve a one-year term.
  • PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box.

PlateletBio Names Derek Adams, Ph.D., as Chief Operating Officer

Retrieved on: 
Thursday, July 8, 2021
Biotechnology, General Health, Other Health, Health, Stem cells, Medical specialties, Vaccination, Vaccine, Virology, Merck & Co., Health care, Health sciences

Dr. Adams started his manufacturing career with Merck & Co, Inc. as a Process Engineer for vaccine production technologies.

Key Points: 
  • Dr. Adams started his manufacturing career with Merck & Co, Inc. as a Process Engineer for vaccine production technologies.
  • I have had the opportunity to help multiple organizations rapidly scale product development and manufacturing to successful launch and commercialization.
  • I look forward to joining the accomplished team at PlateletBio as we work together to advance the company to its next phases of growth.
  • Inspired by the biological function and versatility of platelets, PlateletBio is pioneering the next generation of safer, more effective allogeneic cell therapies.

Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere™ Technology

Retrieved on: 
Thursday, July 8, 2021
Science, Stem cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Commodore International, MOS Technology, MOS, Tumor microenvironment, Economy of Pennsylvania, PENNSYLVANIA, Economy of the United States

Xilis, Inc., a pioneering company using its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, today announced the close of a $70 million Series A financing.

Key Points: 
  • Xilis, Inc., a pioneering company using its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, today announced the close of a $70 million Series A financing.
  • They have developed the scalable MOS technology to analyze patients own tumors in their native microenvironment a breakthrough achievement.
  • Proceeds from the Series A funding will further advance Xilis proprietary MOS technology, expand its AI-driven capabilities, fund clinical studies for diagnostic development, and validate the use of MOS technology with biopharma partners.
  • Xilis proprietary MicroOrganoSphere (MOS) technology consists of miniature patient tumors that capture the full microenvironment and heterogeneity and provides an automated and scalable solution.

Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)

Retrieved on: 
Thursday, July 8, 2021
Branches of biology, Medical specialties, Stem cells, Biology, Hematology, Acute myeloid leukemia, Hematopoietic stem cell transplantation, Cell therapy

Under the terms of the collaboration, Vor Biopharma will investigate the combination of these two technologies into a treatment solution, pairing Vors invisible eHSC transplant platform with one of Janssens bi-specific antibodies in development for acute myeloid leukemia (AML).

Key Points: 
  • Under the terms of the collaboration, Vor Biopharma will investigate the combination of these two technologies into a treatment solution, pairing Vors invisible eHSC transplant platform with one of Janssens bi-specific antibodies in development for acute myeloid leukemia (AML).
  • We believe this unique combination will leverage each technologys strengths, while protecting patients against off-target effects of these powerful immunotherapies.
  • Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies.
  • Forward-looking statements in this press release include the Companys statements regarding its platforms potential to treat patients suffering from acute myeloid leukemia.

Gyros Protein Technologies and Cygnus Technologies Expand Collaboration to Support Improved Bioprocess Impurity Analytics, and Introduce HEK 293 HCP Assay Reagent Set for Gyrolab

Retrieved on: 
Wednesday, July 7, 2021
Science, Stem cells, Biotechnology, Research, Pharmaceutical, Medical Supplies, Health, Genetics, Natural sciences, Bioethics, HEK 293 cells, Assay

The Cygnus HEK 293 HCP Assay Reagent Set for Gyrolab is the first of a planned range of ready-to-use bioprocess impurity reagent sets optimized for use with the Gyrolab platform to be developed by Cygnus as part of the expanded collaboration.

Key Points: 
  • The Cygnus HEK 293 HCP Assay Reagent Set for Gyrolab is the first of a planned range of ready-to-use bioprocess impurity reagent sets optimized for use with the Gyrolab platform to be developed by Cygnus as part of the expanded collaboration.
  • The two companies are now expanding their relationship to develop a range of ready-to-use bioprocess impurity reagent sets optimized for use with the Gyrolab platform.
  • HEK 293 HCP Assay Reagent Set for Gyrolab is the first of this new, high quality range, and we hope to announce further releases in the near future.
  • Today we are happy to welcome the HEK 293 HCP Solution for Gyrolab, which will further help accelerate our viral vector bioprocess workflows.

Reversal of Aging of Human Cartilage, Restoring Youthfulness; the First of Its Kind Feat by Edogawa Hospital, Japan.

Retrieved on: 
Wednesday, July 7, 2021
Health, Stem cells, Hospitals, Surgery, Research, Science, Biotechnology, Skeletal system, Anatomy, Branches of biology, Connective tissue, Autologous cultured chondrocytes on porcine collagen membrane, Cartilage, Hyaline cartilage, Chondrocyte, Masatoshi Koshiba, Koshiba, Joint, Knee cartilage replacement therapy

A conversation between (Late) Prof. Masatoshi Koshiba, (Nobel Laureate, 2002) and Dr. Masahiro Katoh on whether his aging joints could be rejuvenated, inspired orthopedician Dr Shojiro Katoh to develop a path breaking EELS-TALC technique (Enriched with Essentials and Lapped in Scaffold, Transplant-suitable Autologous Leveraged Chondrocytes), making this accomplishment.

Key Points: 
  • A conversation between (Late) Prof. Masatoshi Koshiba, (Nobel Laureate, 2002) and Dr. Masahiro Katoh on whether his aging joints could be rejuvenated, inspired orthopedician Dr Shojiro Katoh to develop a path breaking EELS-TALC technique (Enriched with Essentials and Lapped in Scaffold, Transplant-suitable Autologous Leveraged Chondrocytes), making this accomplishment.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210707005420/en/
    Prof. Masatoshi Koshiba (Nobel Laureate; Sitting Rt.)
  • EELS TALC cultured chondrocytes have all ideal characteristics, worth recommending as the most suitable in ACI and MACI treatments:
    (i) Yielding Hyaline cartilage native to articular joints: